Status: Recruiting
Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.
Participants needed: 78
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Gustavo A Heresi, MD, MSUpdated: Aug 13, 2026Locations: 3
Eligibility criteria
Provision of signed and dated informed consent form [+10]
Current use of insulin, insulin secretagogues (sulfonylureas and meglitinides),... [+13]